10-Q: Vanda Pharmaceuticals Reports Q3 2024 Results, Driven by Fanapt and PONVORY Launches

Vanda Pharmaceuticals' Q3 2024 results show a revenue increase driven by the launch of Fanapt for bipolar disorder and PONVORY for multiple sclerosis, despite ongoing challenges with HETLIOZ generic competition.

Summary

• Vanda Pharmaceuticals reported a net product sales increase to $47.7 million in Q3 2024, up from $38.8 million in Q3 2023.
• The increase was primarily driven by Fanapt sales, which rose to $23.9 million, and the launch of PONVORY, contributing $5.9 million in sales.
• HETLIOZ sales saw a slight increase to $17.9 million, but the company anticipates future declines due to generic competition.
• The company's operating loss was $11 million, compared to a $6 million loss in the same period last year.
• Research and development expenses were $16.8 million, a slight increase from $16.6 million in the prior year.
• Selling, general, and administrative expenses increased significantly to $37.6 million, up from $24.8 million, due to commercial launch activities.
• The company reported a net loss of $5.3 million, or $0.09 per share, compared to a net income of $0.1 million in Q3 2023.
• For the nine months ended September 30, 2024, total revenues were $145.6 million, a slight decrease from $147.4 million in the same period of 2023.
• The company's net loss for the nine months was $14 million, or $0.24 per share, compared to a net income of $4.9 million in the same period of 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is making progress with new product launches and pipeline development, the financial results show a net loss, and there are significant risks related to generic competition and ongoing litigation. The FDA rejection of the tradipitant NDA is also a negative factor.

Positives

• The commercial launch of Fanapt for bipolar I disorder is showing strong initial market response with new patient starts increasing by over 90% in Q3 2024 compared to Q3 2023.
• The company successfully launched PONVORY for the treatment of relapsing forms of multiple sclerosis in Q3 2024.
• Vanda is advancing its pipeline with plans to submit an NDA for milsaperidone in early 2025 and initiate Phase III programs for Fanapt LAI and milsaperidone for major depressive disorder by the end of 2024.
• The company is actively pursuing additional indications for HETLIOZ and PONVORY.
• Vanda is progressing with early-stage programs, including VSJ-110 for dry eye and VPO-227 for cholera.

Negatives

• HETLIOZ sales are expected to decline due to generic competition, which has already impacted sales.
• The company reported a net loss of $5.3 million in Q3 2024, compared to a net income of $0.1 million in Q3 2023.
• Operating expenses increased significantly, particularly in selling, general, and administrative costs, due to commercial launch activities.
• The FDA declined to approve the NDA for tradipitant for the treatment of symptoms of gastroparesis.
• The company is facing ongoing legal challenges related to HETLIOZ patents and generic competition.

Risks

• The company faces significant risks related to generic competition for HETLIOZ, which could materially impact revenues.
• The company's ability to achieve profitability depends on the successful commercialization of its products and obtaining regulatory approvals.
• The company is dependent on third-party manufacturers for its products.
• The company faces risks related to intellectual property rights and patent litigation.
• The company's future cash requirements depend on its ability to generate revenue and the costs of its commercial and development activities.
• The company may need to obtain additional capital in the future, which may not be available on acceptable terms.
• The company is subject to risks related to changes in healthcare regulations and reimbursement policies.
• The company is involved in multiple legal proceedings, which could have a material adverse effect on its business.

Future Outlook

Vanda expects to submit an NDA for milsaperidone in early 2025, initiate Phase III programs for Fanapt LAI and milsaperidone for major depressive disorder by the end of 2024, and submit an NDA for tradipitant for motion sickness in Q4 2024. The company also plans to continue pursuing regulatory approvals for HETLIOZ and PONVORY for additional indications.

Management Comments

• The company initiated the commercial launch of Fanapt for bipolar I disorder in adults in the third quarter of 2024, which included the expansion of our existing sales force and the introduction of prescriber awareness and comprehensive marketing programs.
• We initiated the commercial launch of PONVORY for the treatment of relapsing forms of multiple sclerosis in the third quarter of 2024, which included the deployment of a specialty sales force.
• We plan to continue to pursue the marketing authorization for tradipitant and support the expanded access program that is currently serving several dozen patients with gastroparesis.

Industry Context

The pharmaceutical industry is facing increasing competition, particularly from generic manufacturers. Vanda's results reflect the challenges of maintaining market share for branded drugs in the face of generic entry, as seen with HETLIOZ. The company is attempting to mitigate this risk by expanding its product portfolio and pursuing new indications for existing drugs. The launches of Fanapt for bipolar disorder and PONVORY for multiple sclerosis are strategic moves to diversify revenue streams and reduce reliance on HETLIOZ.

Comparison to Industry Standards

• Vanda's revenue growth in Q3 2024, driven by new product launches, is a positive sign compared to companies solely reliant on mature products facing generic competition.
• The increase in selling, general, and administrative expenses is typical for a company launching new products, but the magnitude of the increase may be higher than some peers.
• The company's R&D spending is consistent with other biopharmaceutical companies focused on developing new therapies.
• The net loss reported by Vanda is not uncommon for companies in the growth phase, particularly those investing heavily in commercialization and R&D.
• Compared to companies like Teva and Apotex, who are generic manufacturers, Vanda is focused on branded pharmaceuticals and faces different challenges and opportunities.
• Vanda's legal battles are not unique in the pharmaceutical industry, where patent litigation is a common occurrence.

Legal Proceedings

• The company is involved in multiple legal proceedings related to HETLIOZ patents and generic competition.
• The company is challenging the FDA's rejection of its supplemental New Drug Application (sNDA) for HETLIOZ for the treatment of jet lag disorder in the U.S. Court of Appeals for the D.C. Circuit.
• The company is litigating HETLIOZ Patent No. 11,285,129 against generic manufacturers in the U.S. District Court for the District of Delaware.
• The company is involved in litigation against MSN, Impax, and Amneal alleging fraudulent inducement of a license agreement.
• The company is involved in multiple lawsuits against the FDA to compel the production of records under the Freedom of Information Act (FOIA).
• The company is involved in a lawsuit against the Centers for Medicare & Medicaid Services (CMS) challenging a rule interpreting the terms line extension and new formulation.
• The company is involved in a lawsuit against the FDA challenging the denial of Fast Track designation for tradipitant.
• The company is involved in a lawsuit against the FDA to compel compliance with obligations under the FDCA related to its sNDA for HETLIOZ in the treatment of jet lag disorder.
• The company is involved in a lawsuit against the federal government for the uncompensated taking and misuse of the company's trade secrets and confidential information.
• The company is involved in a lawsuit against the FDA to compel compliance with obligations under the FDCA related to its sNDA for HETLIOZ in the treatment of insomnia.
• The company is involved in a petition for review in the U.S. Court of Appeals for the District of Columbia Circuit seeking review of the FDA's final order refusing to hold a hearing or to approve the company's sNDA for HETLIOZ in the treatment of jet lag disorder.
• The company is involved in a lawsuit against the FDA challenging FDA decisionmakers authority under the Appointments Clause of the U.S. Constitution to render a decision on Vanda's new drug application for tradipitant to treat symptoms of gastroparesis.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, including the net loss and the risks associated with generic competition and litigation.
• Employees are impacted by the company's growth and commercialization activities, as well as the ongoing research and development efforts.
• Patients are impacted by the availability of new treatments and the company's efforts to expand access to its products.
• Customers, including wholesalers, specialty pharmacies, and specialty distributors, are impacted by the company's product sales and distribution strategies.
• Suppliers are impacted by the company's manufacturing and supply chain activities.
• Creditors are impacted by the company's financial performance and its ability to meet its obligations.

Next Steps

• Submit a New Drug Application (NDA) for milsaperidone in early 2025.
• Initiate a Phase III program for the long-acting injectable (LAI) formulation of Fanapt in the fourth quarter of 2024.
• Initiate a Phase III program for milsaperidone for major depressive disorder (MDD) by the end of 2024.
• Submit an NDA for tradipitant for the treatment of motion sickness to the FDA in the fourth quarter of 2024.
• Complete IND applications for PONVORY in the treatments of psoriasis and ulcerative colitis in the fourth quarter of 2024.
• Initiate a clinical trial to study tradipitant in the prevention of vomiting induced by a GLP-1 analog (semaglutide) in the fourth quarter of 2024.
• Proceed with studies of VSJ-110 for the treatment of dry eye disorder.
• Initiate a Phase I study for VPO-227 for the treatment of cholera in Bangladesh by the end of 2024.
• Enroll a patient in the Phase I clinical study for VCA-894A for the treatment of Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S) by the end of 2024.
• Obtain results from the Phase I clinical study for VTR-297 for the treatment of onychomycosis by the end of 2024.

Key Dates

Keywords

Vanda Pharmaceuticals, Fanapt, HETLIOZ, PONVORY, milsaperidone, tradipitant, bipolar disorder, schizophrenia, multiple sclerosis, Non-24, Smith-Magenis Syndrome, gastroparesis, motion sickness, clinical trials, FDA approval, generic competition, pharmaceuticals, biotechnology